Every batch of Labrat Peptides undergoes third-party Mass Spectrometry and HPLC analysis. We believe in absolute transparency - since in third-party marketing we need complete confidence.
Eloralintide/Retatrutide Blend 13mg is a research material supplied for controlled laboratory investigation, analytical testing, biochemical research, peptide characterization, receptor research, and scientific study.
This research blend contains **eloralintide**, an investigational selective amylin receptor agonist, and **retatrutide**, an investigational triple hormone receptor agonist targeting the GIP, GLP-1, and glucagon receptors. These compounds are being studied in research involving metabolic signaling, energy balance, body composition, glucose regulation, and related biological pathways.
The Eloralintide/Retatrutide Blend 13mg offered by LabRat Peptides is intended strictly for **Research Use Only (RUO)**.
It is not intended for human consumption, self-administration, therapeutic use, clinical treatment, diagnosis, disease prevention, veterinary use, or food applications.
Researchers can explore additional Research Peptides and scientific information through the LabRat Peptides Research Hub.
---
Eloralintide/Retatrutide Blend is a research formulation containing two distinct investigational peptide compounds:
* **Eloralintide** — a selective, long-acting amylin receptor agonist.
* **Retatrutide** — an investigational GIP, GLP-1, and glucagon receptor triagonist.
Eloralintide is being investigated for its interaction with amylin-related signaling pathways. Lilly describes it as a selective long-acting amylin receptor agonist and has studied it in clinical development programs involving obesity and related metabolic research.
Retatrutide is being investigated as a multi-receptor agonist that acts on the **GIP receptor, GLP-1 receptor, and glucagon receptor**. Lilly's current development pipeline identifies retatrutide as a large-molecule investigational therapy being studied in obesity, osteoarthritis, and obstructive sleep apnea research.
Because these are separate compounds with different molecular structures and biological targets, the blend should be described according to the exact composition and batch documentation supplied by the manufacturer.
---
| Specification | Information |
| Product Name | Eloralintide/Retatrutide Blend 13mg |
| Components | Eloralintide + Retatrutide |
| Eloralintide Type | Selective long-acting amylin receptor agonist |
| Retatrutide Type | GIP/GLP-1/glucagon receptor triagonist |
| Total Research Quantity | 13mg |
| Primary Research Areas | Metabolic signaling, peptide pharmacology, receptor biology, body-composition research |
| Classification | Research Use Only |
PubChem identifies eloralintide as **C201H319N49O65S2**, with a computed molecular weight of approximately **4526 g/mol**. PubChem lists eloralintide under CAS **2883634-40-8** and also identifies the compound as AT53786.
PubChem records retatrutide-related chemical information under its sodium-salt form, with the molecular formula **C221H342N46O68** and a molecular weight of approximately **4731 g/mol**.
Because peptide salts, counterions, and formulation states can affect molecular-weight specifications, researchers should use the exact chemical form and batch-specific Certificate of Analysis when recording analytical information.
---
Eloralintide is an investigational peptide being studied as a **selective, long-acting amylin receptor agonist**.
Amylin is a peptide hormone involved in physiological processes associated with energy balance, nutrient regulation, and glucose-related biology. Eloralintide has been investigated as a long-acting research compound for understanding amylin receptor signaling and related metabolic pathways.
Research involving eloralintide may examine:
* Amylin receptor signaling
* Energy-balance pathways
* Metabolic signaling
* Appetite-related biological mechanisms
* Body-composition research
* Glucose-related biology
* Peptide-receptor interactions
* Peptide pharmacology
Lilly reports that eloralintide completed Phase 1 and Phase 2 clinical studies and has been advanced into further clinical development.
Clinical research findings provide scientific context but should not be interpreted as evidence that laboratory research material is suitable for human use.
---
# Retatrutide Research
Retatrutide is an investigational peptide-based **triple hormone receptor agonist**.
Unlike compounds that primarily target one receptor pathway, retatrutide has been developed to interact with three metabolic hormone receptors:
* GIP receptor
* GLP-1 receptor
* Glucagon receptor
This multi-receptor activity makes retatrutide relevant to research involving metabolic signaling, energy balance, glucose regulation, lipid metabolism, and body-composition biology. Lilly's research pipeline currently identifies retatrutide as an investigational GIP/GLP-1/glucagon receptor agonist.
Researchers investigating retatrutide may study:
* GIP receptor signaling
* GLP-1 receptor signaling
* Glucagon receptor signaling
* Multi-receptor pharmacology
* Metabolic pathways
* Glucose metabolism
* Lipid metabolism
* Energy balance
* Body-composition biology
* Peptide-receptor interactions
---
# Eloralintide and Amylin Signaling
Amylin signaling represents an important area of metabolic research.
Eloralintide has been characterized as a selective long-acting amylin receptor agonist, making it relevant to studies examining the biological effects of amylin receptor activation and downstream metabolic pathways.
Research applications may include:
* Amylin receptor pharmacology
* Hormonal signaling
* Energy homeostasis
* Metabolic regulation
* Peptide-receptor interactions
* Cellular signaling
* Body-composition research
Researchers should interpret experimental findings according to the specific model, methodology, and study design used.
---
# Retatrutide and Multi-Receptor Signaling
Retatrutide provides a research model for investigating simultaneous activity across three hormone-receptor pathways.
The compound is being studied as a GIP, GLP-1, and glucagon receptor agonist.
* GIP signaling
* GLP-1 signaling
* Glucagon signaling
* Receptor cross-talk
* Metabolic regulation
* Glucose homeostasis
* Lipid metabolism
* Energy expenditure
* Body-composition biology
* Endocrine signaling
The interaction between these pathways is an active area of metabolic and pharmacological research.
---
# Eloralintide/Retatrutide Blend Research Applications
The combination of two distinct investigational compounds creates a research material relevant to studies involving multiple metabolic signaling systems.
### Metabolic Research
Researchers may investigate relationships between amylin-related signaling and incretin/glucagon pathways.
### Peptide Pharmacology
The individual compounds can be studied for peptide-receptor interactions, molecular characteristics, and pharmacological behavior.
### Receptor Signaling Research
The blend provides research context involving amylin receptors alongside GIP, GLP-1, and glucagon receptor pathways.
### Body-Composition Research
Both compounds have been investigated in research programs involving body-composition-related endpoints, providing scientific context for metabolic research.
### Analytical Peptide Research
Researchers can investigate peptide identity, purity, molecular mass, and other analytical characteristics using validated laboratory techniques.
### Endocrine and Metabolic Biology
The individual components are relevant to research involving hormonal signaling, energy regulation, glucose biology, and metabolic pathways.
---
Peptide characterization is an important component of research-material quality assessment.
Eloralintide has a reported molecular weight of approximately **4526 g/mol**, while PubChem reports approximately **4731 g/mol** for the sodium-salt form of retatrutide.
Laboratories may use analytical techniques such as:
* High-performance liquid chromatography (HPLC)
* Reverse-phase HPLC
* Liquid chromatography–mass spectrometry (LC-MS)
* Mass spectrometry
* Molecular-weight determination
* Peptide identity testing
* Purity analysis
The appropriate analytical methodology depends on the research objective and laboratory protocol.
For commercial research materials, the batch-specific Certificate of Analysis should be used to verify the exact composition and analytical specifications of the supplied material.
---
Researchers should review quality documentation before incorporating research peptides into laboratory workflows.
Depending on the testing program, a Certificate of Analysis may include:
* Product identification
* Batch number
* Lot number
* Component identification
* Analytical purity
* HPLC analysis
* Mass-spectrometry results
* Identity testing
* Molecular-weight analysis
* Appearance
* Testing date
* Laboratory information
For a blended research material, researchers should also verify how the **13mg total quantity is allocated between eloralintide and retatrutide** according to the product specification and batch documentation.
Avoid relying solely on generic purity statements when batch-specific analytical documentation is available.
---
A Certificate of Analysis (COA) is an important document for research-material traceability.
For Eloralintide/Retatrutide Blend 13mg, researchers should verify:
* Product name
* Lot number
* Batch number
* Component identity
* Blend composition
* Analytical purity
* Identity
* HPLC results
* Mass-spectrometry results
* Molecular-weight results
* Date of analysis
The COA should correspond to the exact batch of Eloralintide/Retatrutide Blend 13mg being evaluated.
Maintaining the COA alongside the research material can help laboratories maintain accurate research records.
---
# Eloralintide/Retatrutide Storage and Handling
Eloralintide/Retatrutide Blend 13mg should be stored according to the specific product documentation and batch-specific COA.
* Temperature
* Moisture
* Light
* Container integrity
* Temperature fluctuations
* Storage duration
Researchers should avoid unnecessary exposure of peptide materials to environmental conditions and follow the storage requirements supplied with the specific product.
For general educational information, researchers can consult appropriate laboratory documentation and institutional procedures for handling lyophilized research materials.
---
# Eloralintide/Retatrutide Laboratory Safety
Eloralintide/Retatrutide Blend should be handled by appropriately trained laboratory personnel.
* Product handling
* Laboratory access
* Personal protective equipment
* Storage
* Inventory management
* Batch identification
* Waste management
* Research documentation
Researchers are responsible for ensuring that research materials are used in accordance with applicable regulations and institutional requirements.
---
Both eloralintide and retatrutide have been investigated in clinical research, but they remain distinct investigational compounds with different mechanisms of action.
Lilly describes eloralintide as a selective, long-acting amylin receptor agonist and reports clinical development in obesity-related research.
Lilly describes retatrutide as an investigational GIP/GLP-1/glucagon receptor agonist and currently lists it in its clinical development pipeline.
Lilly reported positive Phase 3 retatrutide results in 2025 and additional Phase 3 results in 2026, while continuing to identify retatrutide as investigational.
Clinical research involving these compounds should be considered scientific background only and should not be interpreted as a recommendation to use laboratory research material in humans.
---
Researchers interested in Eloralintide/Retatrutide research can consult scientific databases and primary literature relating to the individual compounds.
### Eloralintide
PubChem provides molecular and chemical information for eloralintide, including its molecular formula, molecular weight, identifiers, and structural information.
### Retatrutide
PubChem provides chemical information for retatrutide-related records, including molecular formula and molecular-weight information for the sodium-salt form.
### Retatrutide Clinical Research
Retatrutide has been investigated in clinical development programs involving metabolic and cardiometabolic research. Lilly's current development pipeline provides an overview of its ongoing investigational programs.
### Eloralintide Clinical Research
Eloralintide has undergone Phase 1 and Phase 2 clinical investigation and has progressed into further clinical development.
---
**FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE.**
Eloralintide/Retatrutide Blend 13mg is supplied as laboratory research material for scientific investigation, analytical testing, peptide characterization, biochemical research, receptor research, and related laboratory applications.
* Human consumption
* Self-administration
* Therapeutic use
* Clinical treatment
* Disease diagnosis
* Disease prevention
* Veterinary use
* Food applications
* Cosmetic applications
Scientific literature referenced on this page is provided for research and educational context and should not be interpreted as a recommendation for human use.
---
### What is Eloralintide/Retatrutide Blend?
Eloralintide/Retatrutide Blend is a research material containing two distinct investigational peptide compounds: eloralintide and retatrutide.
### What is Eloralintide?
Eloralintide is an investigational selective, long-acting amylin receptor agonist being studied in metabolic and obesity-related research.
### What is Retatrutide?
Retatrutide is an investigational peptide-based triple hormone receptor agonist that targets the GIP, GLP-1, and glucagon receptors.
### Is Eloralintide the same as Retatrutide?
No. They are different peptide compounds with different molecular structures and receptor targets.
Eloralintide is associated with selective amylin receptor agonism, while retatrutide acts on GIP, GLP-1, and glucagon receptors.
### What is Eloralintide/Retatrutide Blend 13mg?
It is a research-material presentation containing a total labeled quantity of 13mg of the two peptide components. The exact allocation between the components should be verified from the product specification and batch-specific COA.
### What is Eloralintide used to research?
Eloralintide research includes amylin receptor signaling, metabolic biology, energy-balance pathways, peptide pharmacology, and body-composition-related research.
### What is Retatrutide used to research?
Retatrutide research includes GIP, GLP-1, and glucagon receptor signaling, metabolic pathways, glucose biology, lipid metabolism, energy balance, and multi-receptor pharmacology.
### Is Retatrutide a GLP-1 peptide?
Retatrutide is not a selective GLP-1 receptor agonist. It is an investigational **triple agonist** targeting GIP, GLP-1, and glucagon receptors.
### Is Eloralintide a GLP-1 peptide?
No. Eloralintide is described as a selective amylin receptor agonist and belongs to a different receptor-signaling category.
### What is the molecular weight of Eloralintide?
PubChem reports a computed molecular weight of approximately **4526 g/mol** for eloralintide.
### What is the molecular formula of Eloralintide?
PubChem lists the molecular formula as **C201H319N49O65S2**.
### What is the molecular weight of Retatrutide?
PubChem reports approximately **4731 g/mol** for the recorded sodium-salt form of retatrutide.
### Has Eloralintide been studied clinically?
Yes. Eloralintide has completed Phase 1 and Phase 2 clinical studies and has progressed into further clinical development.
### Has Retatrutide been studied clinically?
Yes. Retatrutide has undergone clinical research, including Phase 3 development programs. Lilly continues to identify it as an investigational compound.
### Is Eloralintide/Retatrutide Blend 13mg intended for human use?
No. LabRat Peptides' research material is supplied strictly for Research Use Only and is not intended for human or veterinary use.
### Where can I find molecular information about these compounds?
Researchers can review chemical and structural information through PubChem and consult primary scientific literature and clinical-trial publications for research findings.
### Where can I find other research peptides?
Researchers can explore the LabRat Peptides Research Peptide Collection for additional laboratory research materials.
---
# Explore More Research Peptides
Researchers interested in eloralintide research, retatrutide research, amylin signaling, GIP/GLP-1/glucagon receptor research, metabolic biology, peptide pharmacology, body-composition research, receptor signaling, and analytical peptide testing can explore the LabRat Peptides Research Peptide Collection.
For scientific and educational information, visit the LabRat Peptides Research Hub.
For general information about handling lyophilized research materials, researchers should follow the storage, handling, and laboratory-safety documentation supplied with each product.
---
# Important Research Disclaimer
**FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE.**
Eloralintide/Retatrutide Blend 13mg is supplied as laboratory research material for scientific investigation, analytical testing, peptide characterization, biochemical research, receptor research, and related laboratory applications.
The information presented on this page is intended for scientific and educational purposes. Published clinical research does not establish that a laboratory research material is appropriate for human use.
Researchers are responsible for ensuring that research materials are used in accordance with applicable laws, regulations, institutional policies, laboratory procedures, and approved research protocols.
| Sequence | Available on COA |
| Appearance | White Lyophilized Powder |
| Mol. Weight | 1419.6 g/mol |
| Purity | 99.2% |
| Storage | -20°C or below |
All peptides and research chemicals sold on this site are intended exclusively for in-vitro laboratory research. They are not approved for human consumption, medical treatment, veterinary use, or any in-vivo application.
